Menu

Workforce Development

A strong, diverse public health workforce is critical to meeting the world’s pressing health challenges and addressing inequities. When health and public health professionals look like and come from the communities they serve, patients receive better care and experience better health outcomes. PHI is creating a pipeline of dedicated public health professionals in California, across the United States and around the world, including finding creative ways to bring those traditionally overlooked in public health careers into the workforce with meaningful salaries and effective training. We build and staff programs that connect residents and youth with opportunities to enter into health professions, while also providing ongoing training, wrap-around services, mentoring and support—helping to create sustainable, community-based expertise. Our partners include public health and community stakeholders, schools, health employers, community development institutions, local health departments, government agencies including USAID and CDC, and more. Together, we’re building the public health workforce of tomorrow and bolstering community power today.

Our expertise can make your work stronger

See how PHI can work with you to support or lead your work on this issue.

Work With Us

You change the world. We do the rest. Explore fiscal sponsorship at PHI.

Bring Your Work to PHI

Support Us

Together, we can accelerate our response to public health’s most critical issues.

Donate

Find Employment

Begin your career at the Public Health Institute.

See Jobs

Close

Breakthrough Infection Study of Over 600,000 Veterans Shows Declining COVID-19 Vaccine Protection

A new pre-print study of over 600,000 veterans by researchers from PHI and the Veterans Affairs Medical Center finds that overall COVID-19 vaccine protection declined significantly between February and August 2021. Declines were greatest for the Johnson & Johnson vaccine (from 88% in March to 3% in August), followed by PfizerBioNTech (91% to 50%) and Moderna (92% to 64%).

More

Continue to PHI.org